Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

7,000

    PEREGRINE PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

                                                  OCTOBER 31,     APRIL 30,
                                                    2008            2008
                                                  Unaudited

    LIABILITIES AND STOCKHOLDERS' EQUITY

    CURRENT LIABILITIES:
    Accounts payable                              $3,419,000    $2,060,000
    Accrued clinical trial site fees                 550,000       237,000
    Accrued legal and accounting fees                225,000       450,000
    Accrued royalties and license fees               113,000       222,000
    Accrued payroll and related costs                782,000     1,084,000
    Capital lease obligation, current portion         23,000        22,000
    Deferred revenue                               6,472,000     2,196,000
    Deferred government contract revenue           1,701,000             -
    Customer deposits                              1,575,000       838,000
    Other current liabilities                        372,000       331,000

          Total current liabilities               15,232,000     7,440,000

    Capital lease obligation, less current
     portion                                          10,000        22,000
    Commitments and contingencies

    STOCKHOLDERS' EQUITY:
    Preferred stock-$.001 par value;
     authorized 5,000,000 shares; non-voting;
     nil shares outstanding                                -             -
    Common stock-$.001 par value; authorized
     325,000,000 shares; outstanding -
     226,210,617 and 226,210,617,
     respectively                                    226,000       226,000
    Additional paid-in capital                   246,698,000   246,205,000
    Accumulated deficit                         (240,419,000) (230,836,000)

          Total stockholders' equ
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, Fadhits.com, a ... collection of elegant long graduation dresses to its ... promotion for its loyal clients. It wants to bring more ... items are now offered at discounted prices, up to 72% ... company is always working hard. Its online shop is a ...
(Date:7/12/2014)... 2014 The Passenger Information System market ... to $20,341.36 million by 2019, at an expected CAGR ... , The public transport infrastructure in North America is ... in almost every corner of the region. The growing ... public transport service providers are driving the North American ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... TX (PRWEB) July 12, 2014 ... market research report, ‘cognitive assessment and training’ ... to monitor, assess, train, or enhance cognitive ... uses such as in dementia screening, clinical ... management, classroom learning, self assessment, brain training, ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5
... to a paper presented at American College of Cardiology, ... The chief presenter of the paper Michael Miller, MD, ... professor of medicine at the University of Maryland in ... participants, 150 healthy and 150 people suffering cardiac problems. ...
... Switzerland it was seen that the frequency of withholding ... a patient’s life varies greatly among European countries. The ... in diagnostics and treatment to save and sustain life. ... patient’s life, physicians may refrain from using all possible ...
... Researchers say they may have discovered a potential form ... ,More than 1 million Americans are estimated to ... forms of inflammatory bowel disease. The conditions, can be ... the digestive tracts. Patients with inflammatory bowel disease suffer ...
... led by Professor Julie Williams and Professor Michael O'Donovan at ... be the cause of dyslexia in children. An analysis of ... dyslexia was done to identify the gene. The gene has ... and the first study to identify one gene which contributes ...
... According to a recent study researchers say hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with breast cancer, who are otherwise in good health, ... chemotherapy. Studies in the past have shown that secondary ... significantly improves survival for women in their 50s and ... 70 and older. Thus researchers suggest that chemotherapy may ...
Cached Medicine News:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... April 13, 2007 /PRNewswire/ -- Mersana, a,cancer therapeutics ... its lead product candidate, XMT-1001, will,be presented in ... the,American Association of Cancer Research (AACR) taking place ... the abstracts can be,viewed online at the AACR ...
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen ... data presented at the,Academy of Managed Care ... (Interferon beta-1a) is a cost-effective therapy in,multiple ... beta,treatments. Using a comprehensive analysis of medical ...
Cached Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 3
... The PRIMATOM System is a multifunctional ... PRIMUS Linear Accelerator and a SOMATOM ... technology brings image guidance to radiation ... target localization within the treatment room. ...
... SOMATOM Sensation is the highly respected ... coronary branches to visualizing plaque. With its ... industrys fastest rotation time of 0.33s, virtually ... z-Sharp Technology, the system delivers unprecedented diagnostic ...
... The DGH Technology, Inc. Pachmate (DGH 55) ... 6.9 inches long and 3.6 ounces in weight. ... accurate reliable corneal thickness measurements. The Pachmate ... shirt pocket. The Pachmate is rugged in ...
... integrated system that will perform venous occlusion ... You no longer need to manually control ... with and without reactive hyperemia are included. ... for measurements and the frequency with which ...
Medicine Products: